Accessibility Statement

1. Commitment

Sanofi is committed to providing digital solutions that are accessible to the widest possible audience, regardless of ability, disability, race, cultural background, gender, or technological requirements.

This accessibility statement applies to www.infilbray.com.

2. Conformance status

The Web Content Accessibility Guidelines (WCAG) defines requirements for designers and developers to improve accessibility for people with disabilities. It defines three levels of conformance: Level A, Level AA, and Level AAA. This website is partially conformant with WCAG 2.2 Level AA, due to the limitations described below.

3. Known limitations

Despite our best efforts to ensure the accessibility of this website, there may be some limitations. Below is a description of known limitations. Please contact us if you observe an issue not listed below.

  • Headings and structure: Heading levels may not always follow a clear or hierarchical order.
  • Page titles: Some pages may not have titles that clearly or uniquely describe their content.
  • Keyboard accessibility: Skip navigation functionality may not be available on all pages.
  • Non-color indicators: Links may not consistently include visual indicators beyond color alone.


4. Feedback and contact

Please contact us if you encounter accessibility barriers on this website. If you are unable to access any content or service, we will provide an accessible alternative or offer the content in another form.

5. Preparation of this accessibility statement

This statement was prepared on November 4, 2026.


To evaluate the current level of accessibility, the website was assessed using automated testing in Axe DevTools, based on WCAG 2.2 Level AA, with Microsoft Edge. Some manual testing with a keyboard was also performed.


6. Formal complaints


If you are not satisfied with our response to you, you are entitled to escalate a complaint to the national authority.


To file an Americans with Disabilities (ADA) complaint, submit a report with the US Department of Justice, Civil Rights Division, online or by mail. Learn how to file a complaint on the Civil Rights Division website.


Important Safety Information
Important Safety Information
Indication

Before taking INFILBRAY, tell your healthcare provider (HCP) about all of your medical conditions, including if you:

  • Have kidney problems.
  • Have or have had a history of suicidal thoughts or actions, depression, or any other mental health problem.
  • Are pregnant or plan to become pregnant. INFILBRAY may harm your unborn baby. Females who are able to become pregnant:
    • Your HCP will do a pregnancy test before you start treatment.
    • Use effective birth control during treatment and for 11 days after your last dose.
    • Tell your HCP right away if you become pregnant or think that you may be pregnant during treatment.
  • Are breastfeeding or plan to breastfeed. It is not known if INFILBRAY passes into your breast milk. Talk to your HCP about the best way to feed your baby. If you breastfeed during treatment, your baby may need eye exams with an eye specialist (ophthalmologist).


Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking INFILBRAY with certain other medicines may affect how it works and increase the risk of side effects.

What are the possible side effects of INFILBRAY?

INFILBRAY may cause serious side effects including:

Suicidal thoughts or actions.
INFILBRAY may cause suicidal thoughts or actions, depression, or other mood changes. Before starting treatment, your HCP will check your risk for mental health problems. Pay close attention to and tell your HCP about any behavior changes, especially suicidal thoughts or actions, new or worsening changes in depression, mood, behaviors, thoughts, or feelings.

Tell your HCP right away if you have any of the following symptoms, especially if they are new, worse, or worry you: thoughts about suicide or dying, suicide attempts, depression, anxiety, feeling very agitated or restless, panic attacks, trouble sleeping (insomnia), irritability, acting aggressive, being angry or violent, acting on dangerous impulses, an extreme increase in activity and/or talking (mania), or other unusual changes in behavior or mood.

Your HCP may stop treatment with INFILBRAY if you develop mental health problems.

Clouding of the eye’s lens (lens opacification) in children. Cloudiness of the eye lens may happen in children during long-term (chronic) treatment. Children will have their eyes checked by an eye specialist (ophthalmologist) before starting and once a year during treatment. Tell your child’s HCP if your child gets any vision changes during treatment including: clouded, blurred, or dim vision, trouble seeing in sunlight or bright lights, or trouble seeing at night.

The most common side effects of INFILBRAY include: diarrhea, enlarged spleen, nausea, depression, irritation or infection of the stomach and intestine (gastroenteritis), and vomiting.

These are not all of the possible side effects of INFILBRAY.

Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Indication

What is INFILBRAY (venglustat)?
INFILBRAY is a prescription medicine used for the treatment of neurological (nervous system) symptoms in Type 3 Gaucher disease (GD3) in adults and children weighing at least 33 pounds (15 kg).

It is not known if INFILBRAY is safe and effective in children under 33 pounds.

MAT-US-2610589-v1.0-11/2026. Last updated: November 2026